Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erythropoietin-Fc fusion protein
- Development stage
- Unknown
- Lead developer
- GC Biopharma
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
Erythropoietin-Fc fusion protein (rhEPO-Fc) is a long-acting recombinant fusion protein consisting of human erythropoietin (EPO) linked to the Fc portion of human IgG. It is designed to stimulate erythropoiesis by binding to and activating the erythropoietin receptor (EPOR) on erythroid progenitor cells in the bone marrow. The addition of the Fc region extends the circulating half-life of the protein through neonatal Fc receptor (FcRn)-mediated recycling, allowing for less frequent dosing (e.g., once every two to four weeks) compared to conventional recombinant human EPO or darbepoetin alfa. This platform has been pursued by several developers, most notably Genexine (whose version is known as efepoetin alfa or GX-E2) and Shanghai Meiye Biotechnology, primarily for the treatment of anemia associated with chronic renal failure.
- Other names
- recombinant human erythropoietin-Fc fusion proteinefepoetin alfaEPO-Fc
02
Targets
Erythropoietin ReceptorFCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on erythropoietin-Fc fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erythropoietin-Fc fusion protein.